US · Healthcare · Biotechnology
EPS came in at -0.83 against a street estimate of -0.66 — a miss of 25.8%.
Analysts rate Avalo Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $44.08.
| Fund | Stake |
|---|---|
| Deep Track Capital, LP | 6.73% |
| Caligan Partners LP | 5.90% |
| TCG Crossover Management, LLC | 5.63% |
| FMR Inc | 5.37% |
| T. Rowe Price Investment Management,Inc. | 4.03% |
| Adage Capital Partners Gp LLC | 3.22% |
| Soleus Capital Management, L.P. | 3.09% |
| Bvf Inc | 3.04% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 AVALO THERAPEUTICS, INC. — Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash and investments position (June 30, 2026): $472.2 million - Cash and c | 2026-08-06 |
| Results announced · Q3 2026 AVALO THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $472.2 million as of June 30, 2026 • | 2026-08-06 |
| Board / officer change · Q2 2026 AVALO THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics disclosed in this filing BUSINESS & SEGMENT HIGHLIGHTS • Avalo T | 2026-06-23 |
| Company announcement · Q2 2026 AVALO THERAPEUTICS, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company announced advancement of AVTX-010, a long-acting next-generation | 2026-06-16 |
| Board / officer change · Q2 2026 AVALO THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Exchange of 4,294.675 shares of Series C Preferred Stock for newly created Series C-1 | 2026-06-12 |
| Quarterly report · Q1 2026 AVALO THERAPEUTICS, INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Net loss Q1 2026: $19.6 million (vs. $13.1 million in Q1 2025) • Net loss per share: $ | 2026-05-13 |
| Proxy statement · Q2 2026 AVALO THERAPEUTICS, INC. — PROXY STATEMENT SUMMARY CEO COMPENSATION • Garry Neil, M.D., Chief Executive Officer, earned total compensation of $4,223 | 2026-04-10 |
| Annual report FY2025 AVALO THERAPEUTICS, INC. — FORM 10-K SUMMARY (FISCAL YEAR ENDED DECEMBER 31, 2025) HEADLINE NUMBERS • Public Float (as of June 30, 2025): $53.7 mill | 2026-03-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Avalo Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.